Navigation Links
Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
Date:12/6/2012

nd is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 could also have a beneficial effect on the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of the disease.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will announce the remaining data from its Phase 1 clinical trial evaluating OMS824; that it will announce Phase 3 data from its OMS103HP program this month; that it will submit an NDA next quarter for OMS302; that as many as three additional programs will enter the clinic in 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information availa
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
2. Omeros is Not Aware of Any Justification for Share Price Movement
3. Omeros Corporation Reports Third Quarter 2012 Financial Results
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
6. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
7. Omeros to Present at Two Upcoming Conferences
8. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Discovery in MASP-2 Program
11. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data Solutions ... new website design . The main website, along with ... the company,s new services and content relevant to the ... new streamlined design, viewers can now better understand how ... care practices and create a more visible platform about ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ –  Royal ... AEX: PHIA) today announced its ... of Cardiology (ESC) Congress 2014 , where ... of its cardiology solutions serving clinicians and patients ... and diagnosis, to treatment, recovery ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... 21, 2007 - Antigenics Inc.,(NASDAQ: AGEN) today ... 3 investigational therapeutic cancer vaccine,Oncophage(R) (vitespen). The ... data collection, showed that in a substantial,subset ... risk for disease,recurrence, Oncophage demonstrated a clinically ...
... FDA for long-term,maintenance treatment of COPD bronchoconstriction; ... lung function,comparable to dry powder formoterol, enhanced ... -- , NAPA, CA (May 20, 2007) ... the American Thoracic Society (ATS),demonstrate that Perforomist™ ...
Cached Medicine Technology:Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:8/29/2014)... August 29, 2014 According to new research ... Not Peer Pressure, Key to Prescription Drug Misuse Among Young ... focus for 18-29 year olds when it comes to prescription ... for this age group the real problem which influences misuse ... associations and recreational use of them to have fun with ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... which will give patients the convenience of visiting ... with Healthpointe doctors through telemedicine. , Healthpointe doctors are ... calls (or audio). If necessary, the doctor can even ... assessed the patient’s condition, he or she can prescribe ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Healthpointe ... J. Chuang, has joined their practice. Dr. Chuang garners ... and specializes in minimally-invasive arthroscopic and reconstructive treatments of ... care for patients with general and sports-related orthopedic needs. ... in the medical field. As an Orange County native, ...
Breaking Medicine News(10 mins):Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you,re ... recall due to salmonella contamination has probably made you refrain from ... now some time has passed, and you,re starting to crave an ... languishing in your fridge or are you inviting a bout of ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... caloric overindulgence can be easily worked off at the gym, ... a month,s worth of unhealthy living changes physiology, making piled-on ... [over-eating] can have later long-term effects," said study co-author Dr. ...
... in seven patients experience more pain, physical and emotional problems ... quarter have less vitality. Those are the key findings of ... by the British Journal of Surgery . ... men with an average age of 54, who had undergone ...
... TUESDAY, Aug. 24 (HealthDay News) -- A new study finds ... the glucose-lowering diabetes drugs Avandia and Actos are about the ... studies that found that the risk was elevated for Avandia ... in line with some other previous studies, further muddying the ...
... room waiting times could be cut by over one third ... a new approach to the triage process of sorting ... in the International Journal of Six Sigma and Competitive ... University in Zarqa, Jordan and colleagues have turned to a ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay ... the herpes virus should not worry that their use ... than 1 percent of women develop herpes simplex during ... during pregnancy of antiviral drugs such as acyclovir (Zovirax), ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
... clinical image management. Mediscan is an ... system derived from extensive experience with ... capture, organize, and distribute high quality ... minimum effort. Can be connected to ...
... OxyLite represents a major breakthrough in the ... Based on the principle of oxygen quenching ... quantitative monitoring of regional pO2 in tissue ... been shown to overcome many of the ...
Derrico Perforator Drill and Enlarging Burr...
Hough Hough Burr-Saw for Crurotomy, 1 mm, ISO-No. 010....
Medicine Products: